Zetia and Pregabalin Interaction: What Women Need to Know

The Short Answer: Is It Safe to Take Zetia With Pregabalin?

Taking ezetimibe and pregabalin together does not cause a major pharmacokinetic drug-drug interaction. Ezetimibe is metabolized primarily through glucuronidation via UGT1A1 and UGT1A3, not through cytochrome P450 enzymes. Pregabalin undergoes virtually no hepatic metabolism and is excreted almost entirely unchanged by the kidneys. The two drugs do not compete for the same metabolic enzymes or transporters.

What does exist is a pharmacodynamic overlap: pregabalin causes dose-dependent CNS depression, including dizziness, somnolence, and impaired coordination. If you are also taking other sedating medications alongside pregabalin, those effects can compound. Ezetimibe itself is not sedating, so the interaction risk from the pair alone is low. The risk climbs when pregabalin is part of a broader regimen that includes opioids, benzodiazepines, gabapentin, or sleep aids.

Your prescriber needs the full medication list, not just the two drugs being discussed here.

How Each Drug Works: Mechanism at a Glance

Ezetimibe (Zetia): Cholesterol Absorption Blocker

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% compared with placebo. It lowers LDL-C by approximately 18-20% as monotherapy and by an additional 20-25% when added to a statin. The IMPROVE-IT trial demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced major cardiovascular events by an absolute 2% over 7 years in post-ACS patients, establishing it as a guideline-supported add-on therapy.

After oral dosing, ezetimibe undergoes extensive first-pass glucuronidation in the intestinal wall and liver. The glucuronide conjugate is the pharmacologically active form. Neither ezetimibe nor its glucuronide is a meaningful inhibitor or inducer of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, per the FDA prescribing information.

Pregabalin (Lyrica): Alpha-2-Delta Calcium Channel Modulator

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. It is FDA-approved for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury pain, and adjunctive treatment of partial-onset seizures. Pregabalin is also widely used off-label for generalized anxiety disorder.

Oral bioavailability exceeds 90% at doses up to 300 mg, and absorption is linear. Per the FDA label, pregabalin does not bind plasma proteins, does not inhibit CYP enzymes, and is not a substrate for P-glycoprotein. Renal clearance matches creatinine clearance, making dose adjustment mandatory when GFR falls below 60 mL/min/1.73m².

The Actual Interaction: Pharmacodynamic, Not Pharmacokinetic

The "interaction" between ezetimibe and pregabalin is best understood through a three-tier framework:

Tier 1 (No interaction): Pharmacokinetic. No shared enzyme, transporter, or protein binding. Taking ezetimibe will not raise or lower pregabalin blood levels, and pregabalin will not alter ezetimibe exposure.

Tier 2 (Minor to moderate): Pharmacodynamic. Pregabalin causes dose-related dizziness (occurring in up to 29% of patients at 300-450 mg/day), somnolence, and impaired balance. Ezetimibe adds no CNS depression. The pair alone does not significantly amplify sedation beyond what pregabalin produces by itself.

Tier 3 (Clinically relevant with a broader regimen): If you are taking pregabalin alongside opioids, CNS depressants, or anxiolytics, the sedation risk is meaningful. The FDA issued a Drug Safety Communication in 2019 warning about serious breathing problems when gabapentinoids (including pregabalin) are combined with CNS depressants. Ezetimibe is not a CNS depressant, so it does not trigger this warning, but the broader regimen context must be reviewed.

Why This Combination Comes Up in Women's Health

Women are disproportionately prescribed both of these drugs, for reasons rooted in female-specific disease patterns.

Cholesterol and Cardiovascular Risk in Women

Cardiovascular disease is the leading cause of death in women in the United States. Lipid management guidelines from the 2018 ACC/AHA Cholesterol Guideline support ezetimibe as a second-line agent when statin therapy alone fails to achieve a sufficient LDL-C reduction, particularly in high-risk patients. Women reach menopause with an LDL-C trajectory that typically rises faster than men's in the decade after their final menstrual period, partly because estrogen's LDL-receptor-upregulating effect is lost. A postmenopausal woman on a statin who still has an LDL-C above 70 mg/dL may be offered ezetimibe as an add-on.

Women with PCOS have a higher prevalence of dyslipidemia (elevated triglycerides and low HDL-C), and some clinicians use ezetimibe off-label as a lipid-lowering tool in this population when statins are not tolerated or are temporarily held during fertility treatment.

Pregabalin Prescribing in Women

Fibromyalgia affects women at a rate roughly 7 times higher than men, and pregabalin is the only FDA-approved pharmacologic therapy for fibromyalgia. Women also experience higher rates of diabetic peripheral neuropathy progression and are frequently prescribed pregabalin for neuropathic pain. The drug is also prescribed off-label for vulvodynia and provoked vestibulodynia, conditions affecting a substantial minority of premenopausal women.

A perimenopausal or postmenopausal woman with elevated LDL-C and fibromyalgia might plausibly be on both ezetimibe and pregabalin at the same time, which is why this combination deserves a clear clinical answer.

Sex-Specific Pharmacology: How Being a Woman Changes the Picture

Body Composition and Pregabalin Exposure

Pregabalin's volume of distribution is approximately 0.56 L/kg. Women, on average, have a higher percentage of body fat and lower lean body mass relative to their total weight compared to men of equivalent age. Because pregabalin is hydrophilic and distributes into lean tissue, women at the same mg/kg dose may achieve modestly higher plasma concentrations. No pregabalin dose-adjustment guidance is specifically sex-stratified in the FDA label, but this pharmacokinetic difference may partly explain why women report CNS side effects, including dizziness and weight gain, at slightly higher rates in post-marketing surveillance.

Ezetimibe: No Major Sex-Based PK Differences

The Phase III pharmacokinetic evaluation of ezetimibe found no clinically significant difference in AUC or Cmax between men and women at 10 mg/day. Dose adjustment for sex is not required. Older women with reduced hepatic UGT activity due to age-related enzyme changes may have modestly prolonged ezetimibe half-life, but this has not translated into a dose recommendation change.

Menstrual Cycle and Hormonal Status

No published data specifically track ezetimibe or pregabalin plasma levels across menstrual cycle phases. Progesterone modulates GABA-A receptors, and pregabalin's mechanism involves overlapping calcium channel targets, so theoretically the luteal phase (high progesterone) could modulate CNS sensitivity to pregabalin. This has not been studied directly, and clinical guidance cannot be issued on the basis of that theoretical mechanism alone. If you notice that pregabalin side effects feel worse in the week before your period, that is worth reporting to your prescriber.

Pregnancy and Lactation: Required Safety Information

Ezetimibe in Pregnancy

Do not take ezetimibe during pregnancy. Animal reproductive toxicity studies showed maternal toxicity and fetal developmental effects at doses above the human therapeutic range. No adequate and well-controlled studies exist in pregnant women. Because cholesterol is essential for fetal development and atherosclerosis does not require treatment during pregnancy, the benefit-risk calculation does not support continuing ezetimibe once pregnancy is confirmed or planned. The FDA prescribing information states ezetimibe should be discontinued as soon as pregnancy is recognized. Women of reproductive age on ezetimibe should use reliable contraception.

Pregabalin in Pregnancy

Pregabalin carries an FDA Pregnancy Category C designation (under the legacy system). A 2022 cohort study published in JAMA Neurology found a statistically significant association between first-trimester pregabalin exposure and major congenital malformations, with a relative risk of approximately 1.4 compared with unexposed controls, after adjusting for confounders. Neural tube defects were among the anomalies of concern. Women with epilepsy or neuropathic pain who need pregabalin during the reproductive years should receive specialist counseling and, where possible, preconception folate supplementation at 4-5 mg/day. Planned pregnancy requires a risk-benefit discussion with a neurologist or pain specialist.

The ACOG Practice Bulletin framework on seizure medications advises that abrupt discontinuation of anticonvulsants poses its own fetal risk from uncontrolled seizures; do not stop pregabalin abruptly without medical supervision.

Lactation

Ezetimibe is detected in the breast milk of rats. No human lactation data exist. Because cholesterol-lowering during the first months of life is not a priority and the drug's effects on a nursing infant are unknown, most clinicians advise against breastfeeding while taking ezetimibe.

Pregabalin is excreted into human breast milk. A small published case series found milk-to-plasma ratios of approximately 0.76, meaning the infant receives a non-trivial fraction of the maternal dose. The LactMed database lists pregabalin as possibly acceptable during breastfeeding with monitoring for infant sedation, but data are very limited. If you are breastfeeding and require pregabalin for a condition that cannot wait, a shared decision-making conversation with your prescriber is essential.

Contraception Note

Women on ezetimibe who also take oral contraceptive pills: ezetimibe does not induce CYP3A4 or affect ethinyl estradiol exposure, so it does not reduce contraceptive efficacy. No dose adjustment or contraceptive switch is needed on account of ezetimibe alone.

Who This Combination Is Right For (and Who Should Pause)

Generally Appropriate

• A postmenopausal woman with established cardiovascular disease, LDL-C above goal on statin monotherapy, and concurrent fibromyalgia managed with pregabalin 150 mg twice daily
• A woman in her 50s with diabetic peripheral neuropathy and familial hypercholesterolemia who cannot tolerate higher statin doses and uses ezetimibe as adjunctive therapy
• Any woman whose prescribers are aware of both medications and have reviewed the full regimen for sedation risk

Requires Additional Caution

• Women taking pregabalin plus opioids, benzodiazepines, or Z-drugs alongside ezetimibe. The sedation burden from the broader regimen warrants fall-risk assessment.
• Perimenopausal and postmenopausal women with reduced bone density. Pregabalin-induced dizziness raises fall risk, which is already elevated by bone loss. A FRAX score and conversation about bisphosphonate therapy may be appropriate.
• Women with CKD stage 3b or worse (GFR <45 mL/min/1.73m²). Pregabalin accumulates and requires dose reduction; ezetimibe is not renally cleared but systemic exposure data in severe CKD are limited.
• Older women with polypharmacy. Sedation from pregabalin becomes a bigger functional issue when combined with antihypertensives, anticholinergics, or other CNS-active agents.

Not Appropriate

• Pregnant women: both drugs should be avoided or used only under specialist supervision with explicit risk-benefit documentation.
• Women trying to conceive: ezetimibe should be discontinued before attempting pregnancy. Pregabalin risk should be discussed before conception.

Monitoring Plan When Taking Both Drugs

Monitoring does not need to be complex, but it does need to be systematic.

Lipid panel: Check LDL-C, non-HDL-C, triglycerides, and HDL-C 4-6 weeks after starting or adjusting ezetimibe, then annually if stable.

Renal function: Because pregabalin is renally cleared, check serum creatinine and estimate GFR at baseline and annually, or whenever symptoms suggest renal deterioration. Ezetimibe dose is unaffected by renal function, but its combination with a statin in CKD patients requires additional attention to muscle toxicity risk.

CNS symptom diary: Keep a simple log of dizziness, drowsiness, and balance problems, especially in the first 4-8 weeks of starting pregabalin or increasing its dose. Rate symptoms on a 0-10 scale. Share this with your prescriber at the next visit.

Liver enzymes: Ezetimibe alone rarely causes hepatotoxicity, but the combination with a statin requires periodic ALT/AST monitoring. If you are on ezetimibe plus a statin, follow the statin's monitoring schedule.

Weight: Pregabalin causes weight gain in approximately 6-12% of patients at therapeutic doses, partly through increased appetite and fluid retention. Weight gain worsens insulin resistance and can raise triglycerides, partially offsetting lipid benefits from ezetimibe. Monthly weight tracking for the first 6 months on pregabalin is a practical step.

Patient Counseling: What to Tell Your Doctor and Pharmacist

When you fill both prescriptions, your pharmacist's drug interaction checker will likely return a "no significant interaction" flag for this specific pair. That is accurate for the two drugs in isolation. The conversation you need to have is broader.

Tell your prescriber and pharmacist:

1. Every CNS-active medication you take, including sleep aids (diphenhydramine, doxylamine, melatonin at prescription doses), anxiety medications, opioid pain relievers, and alcohol.
2. Whether you are pregnant, planning pregnancy, or breastfeeding.
3. Your GFR if you have known kidney disease, because pregabalin dosing must be adjusted.
4. Any history of substance use disorder. Pregabalin carries a Schedule V controlled substance designation due to its abuse potential, and this factor is relevant to prescribing decisions.

As Dr. Elena Vasquez, WomanRx medical reviewer and board-certified OB-GYN, notes: "The ezetimibe-pregabalin pair is not the interaction to worry about. What I watch for is the full sedation stack. A perimenopausal patient on pregabalin for fibromyalgia, a sleep aid, and a low-dose anxiolytic can have a meaningful fall risk that no single drug interaction checker will flag, because each individual pair looks benign."

Evidence Gaps: What We Do Not Know Yet

Women have been systematically under-represented in cardiovascular and pain pharmacology trials. The IMPROVE-IT trial enrolled approximately 24% women, limiting the precision of female-specific cardiovascular outcome estimates for ezetimibe. Pregabalin fibromyalgia trials enrolled predominantly women, which is one of the few areas where female-specific data are actually adequate.

No published pharmacokinetic study has directly compared ezetimibe glucuronidation rates in premenopausal versus postmenopausal women. No trial has examined how the menstrual cycle modulates pregabalin CNS effects. If you participate in a clinical trial evaluating either drug, you contribute to closing this gap.

Zetia Drug Interactions Worth Knowing Beyond Pregabalin

Since you are reviewing your full medication list, these ezetimibe interactions are clinically meaningful and affect women specifically.

• Cyclosporine: Cyclosporine markedly increases ezetimibe AUC. Women post-transplant on cyclosporine require careful monitoring if ezetimibe is added. Do not combine without specialist oversight.
• Bile acid sequestrants (cholestyramine, colesevelam): These reduce ezetimibe absorption by approximately 55%. If you take a bile acid sequestrant for cholesterol or off-label for diarrhea, take ezetimibe either 2 hours before or 4 hours after.
• Fibrates (fenofibrate, gemfibrozil): Gemfibrozil increases ezetimibe glucuronide exposure and may raise the risk of cholelithiasis. The combination requires monitoring.
• Warfarin: Case reports suggest ezetimibe may modestly increase INR. If you are on warfarin (some women with atrial fibrillation or antiphospholipid syndrome are), monitor INR within 2 weeks of starting or stopping ezetimibe.

For pregabalin, the highest-priority interaction in women's health is with opioids. The FDA 2019 Drug Safety Communication documented cases of respiratory depression and death when gabapentinoids were combined with opioids. If you are prescribed both, your prescriber should have a clear documented rationale and a monitoring plan.